Cartesian Therapeutics (RNAC) Current Deferred Revenue (2015 - 2024)
Cartesian Therapeutics (RNAC) reported Current Deferred Revenue of $412000.0 for Q1 2024, down 95.77% year-over-year from $9.8 million in Q2 2023, and down 92.96% quarter-over-quarter from $5.8 million in Q4 2023.
Cartesian Therapeutics (RNAC) Current Deferred Revenue (2015 - 2024) Analysis & Trends
Cartesian Therapeutics (RNAC) has 10 years of Current Deferred Revenue data on file, last reported at $412000.0 in Q1 2024.
- Current Deferred Revenue for Q1 2024 came in at $412000.0, down 95.77% year-over-year; the trailing twelve-month figure through Mar 2024 was $412000.0 (down 95.77% YoY), and the FY2023 annual result was $5.8 million, up 886.34% from the prior year.
- Current Deferred Revenue retreated to $412000.0 in Q1 2024 per RNAC's latest filing, from $5.8 million in the prior quarter.
- Over five years, Current Deferred Revenue peaked at $115.8 million in Q3 2020 and troughed at $412000.0 in Q1 2024.
- A 5-year average of $35.1 million and a median of $9.8 million in 2023 frame the typical range for Current Deferred Revenue.
- The sharpest annual moves came in 2020 and 2024: Current Deferred Revenue soared 11223.46% in 2020, then slumped 95.77% in 2024.
- A 5-year view of Current Deferred Revenue shows it stood at $72.0 million in 2020, then slumped by 87.23% to $9.2 million in 2021, then slumped by 93.55% to $593000.0 in 2022, then soared by 886.34% to $5.8 million in 2023, then slumped by 92.96% to $412000.0 in 2024.
- Business Quant data shows RNAC's Current Deferred Revenue at $412000.0 in Q1 2024, $5.8 million in Q4 2023, and $8.1 million in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Cartesian Therapeutics | 261.84 Mn | 261.84 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 412,000.00 |
| Dec 31, 2023 | 5.85 Mn |
| Sep 30, 2023 | 8.12 Mn |
| Jun 30, 2023 | 4.23 Mn |
| Mar 31, 2023 | 9.75 Mn |
| Dec 31, 2022 | 593,000.00 |
| Sep 30, 2022 | 9.26 Mn |
| Jun 30, 2022 | 23.09 Mn |
| Mar 31, 2022 | 27.99 Mn |
| Dec 31, 2021 | 9.20 Mn |
| Sep 30, 2021 | 82.37 Mn |
| Jun 30, 2021 | 99.75 Mn |
| Mar 31, 2021 | 108.07 Mn |
| Dec 31, 2020 | 72.05 Mn |
| Sep 30, 2020 | 115.84 Mn |
| Jun 30, 2020 | 18.34 Mn |
| Mar 31, 2020 | 1.67 Mn |
| Dec 31, 2019 | 16.35 Mn |
| Sep 30, 2019 | 1.02 Mn |
| Jun 30, 2019 | 16.33 Mn |